These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29608774)

  • 1. B-cell activity markers are associated with different disease activity domains in primary Sjögren's syndrome.
    James K; Chipeta C; Parker A; Harding S; Cockell SJ; Gillespie CS; Hallinan J; Barone F; Bowman SJ; Ng WF; Fisher BA;
    Rheumatology (Oxford); 2018 Jul; 57(7):1222-1227. PubMed ID: 29608774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
    Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
    Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort.
    Gottenberg JE; Seror R; Miceli-Richard C; Benessiano J; Devauchelle-Pensec V; Dieude P; Dubost JJ; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Le Guern V; Morel J; Perdriger A; Puéchal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Nocturne G; Ravaud P; Mariette X
    PLoS One; 2013; 8(5):e59868. PubMed ID: 23717383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and mechanism for action of iguratimod in primary Sjögren's syndrome patients.
    Jiang W; Zhang L; Zhao Y; He X; Hu C; Liu Y
    Int Ophthalmol; 2020 Nov; 40(11):3059-3065. PubMed ID: 32607949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome.
    de Wolff L; Arends S; Pontarini E; Bombardieri M; Bowman SJ; Bootsma H
    Clin Exp Rheumatol; 2021; 39 Suppl 133(6):100-106. PubMed ID: 34796851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjögren's syndrome.
    Verstappen GM; Moerman RV; van Nimwegen JF; van Ginkel MS; Bijzet J; Mossel E; Vissink A; Hazenberg BPC; Arends S; Kroese FGM; Bootsma H
    Rheumatology (Oxford); 2018 Oct; 57(10):1812-1821. PubMed ID: 29982712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated expression of BAFF receptor, BR3, on monocytes correlates with B cell activation and clinical features of patients with primary Sjögren's syndrome.
    Yoshimoto K; Suzuki K; Takei E; Ikeda Y; Takeuchi T
    Arthritis Res Ther; 2020 Jun; 22(1):157. PubMed ID: 32576236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum 25-Hydroxyvitamin D3 and BAFF Levels Are Associated with Disease Activity in Primary Sjogren's Syndrome.
    Lee SJ; Oh HJ; Choi BY; Jang YJ; Lee JY; Park JK; Song YW
    J Immunol Res; 2016; 2016():5781070. PubMed ID: 28074193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease activity and damage in patients with primary Sjogren's syndrome: Prognostic value of salivary gland ultrasonography.
    Milic V; Colic J; Cirkovic A; Stanojlovic S; Damjanov N
    PLoS One; 2019; 14(12):e0226498. PubMed ID: 31891590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum transthyretin levels and disease activity in patients with primary Sjögren's syndrome.
    Peng YF; Lu FY; Deng YB
    Ther Adv Musculoskelet Dis; 2024; 16():1759720X241283528. PubMed ID: 39421803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Go Ask Your Patients! PSS-QoL Reported Perception of Dryness Correlates With Lacrimal and Salivary Flow in Primary Sjögren's Syndrome.
    Lackner A; Bosch P; Zenz S; Horwath-Winter J; Rabensteiner DF; Hermann J; Graninger W; Stradner MH
    Front Med (Lausanne); 2021; 8():660580. PubMed ID: 33937295
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies.
    Seror R; Meiners P; Baron G; Bootsma H; Bowman SJ; Vitali C; Gottenberg JE; Theander E; Tzioufas A; De Vita S; Ramos-Casals M; Dörner T; Quartuccio L; Ravaud P; Mariette X;
    Ann Rheum Dis; 2016 Nov; 75(11):1945-1950. PubMed ID: 27150113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
    Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
    Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of definitive serum biomarkers associated with disease activity in primary Sjögren's syndrome.
    Nishikawa A; Suzuki K; Kassai Y; Gotou Y; Takiguchi M; Miyazaki T; Yoshimoto K; Yasuoka H; Yamaoka K; Morita R; Yoshimura A; Takeuchi T
    Arthritis Res Ther; 2016 May; 18(1):106. PubMed ID: 27180164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of systemic activity of pediatric primary Sjögren's syndrome by EULAR Sjögren's syndrome disease activity index (ESSDAI).
    Kobayashi I; Okura Y; Ueki M; Tozawa Y; Takezaki S; Yamada M; Ariga T
    Mod Rheumatol; 2019 Jan; 29(1):130-133. PubMed ID: 29529894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic accuracy of salivary and serum-free light chain assays in primary Sjögren's syndrome: a pilot study.
    Sandhya P; Christudoss P; Kabeerdoss J; Mandal SK; Aithala R; Mahasampath G; Job V; Danda D
    Int J Rheum Dis; 2017 Jun; 20(6):760-766. PubMed ID: 28036132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological lymphocytic activity and patient-reported outcomes in Sjögren's syndrome.
    Jülich M; Kanne AM; Sehnert B; Budweiser S; Voll RE; Kollert F
    Clin Rheumatol; 2018 Sep; 37(9):2361-2366. PubMed ID: 29858711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome.
    Brito-Zerón P; Acar-Denizli N; Ng WF; Horváth IF; Rasmussen A; Seror R; Li X; Baldini C; Gottenberg JE; Danda D; Quartuccio L; Priori R; Hernandez-Molina G; Armagan B; Kruize AA; Kwok SK; Kvarnstrom M; Praprotnik S; Sene D; Gerli R; Solans R; Rischmueller M; Mandl T; Suzuki Y; Isenberg D; Valim V; Wiland P; Nordmark G; Fraile G; Bootsma H; Nakamura H; Giacomelli R; Devauchelle-Pensec V; Hofauer B; Bombardieri M; Trevisani VFM; Hammenfors D; Pasoto SG; Retamozo S; Gheita TA; Atzeni F; Morel J; Vollenweider C; Zeher M; Sivils K; Xu B; Bombardieri S; Sandhya P; De Vita S; Minniti A; Sánchez-Guerrero J; Kilic L; van der Heijden E; Park SH; Wahren-Herlenius M; Mariette X; Ramos-Casals M;
    Rheumatology (Oxford); 2020 Sep; 59(9):2350-2359. PubMed ID: 31873754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity.
    Mandl T; Marsal J; Olsson P; Ohlsson B; Andréasson K
    Arthritis Res Ther; 2017 Oct; 19(1):237. PubMed ID: 29065905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) and Other Patient-Reported Outcomes in the Assessment of Glandular Dysfunction in Primary Sjögren's Syndrome.
    Ture HY; Kim NR; Nam EJ
    Life (Basel); 2023 Sep; 13(10):. PubMed ID: 37895373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.